Why the study?
Does intravenous ganciclovir improve cardiac muscle contractility in an immunocompetent infant with cytomegalovirus myocarditis?
Population
15-month-old immunocompetent healthy girl with acute, severe myocarditis caused by cytomegalovirus infection
Design
Case_report
Follow-up
long follow-up period
Authors
Loading...
May support ganciclovir in CMV myocarditis; hypothesis-generating and should not yet change practice.
Does intravenous ganciclovir improve cardiac muscle contractility in an immunocompetent infant with cytomegalovirus myocarditis?
Intravenous ganciclovir may be an effective treatment for acute cytomegalovirus myocarditis even in immunocompetent infants.
Dehtiar et al. (2001) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: